This World Kidney Day (13 March 2025), Boehringer Ingelheim (BI) has announced a new initiative aimed at detecting, ...
Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy and primary ...
The National Institute for Health and Care Excellence (NICE) has recommended Gideon Richter’s Ryeqo (relugolix, estradiol and ...
Roche and Zealand Pharma have entered into a partnership worth up to $5.3bn to advance Zealand’s mid-stage obesity candidate ...
Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence ...
Amgen and Kyowa Kirin have shared promising results from a phase 3 programme of their investigational T-cell rebalancing ...
Under the terms of the agreement, Kyorin will receive $55m upfront and will be eligible for milestone payments of up to ...
Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) treatment has been approved by the Medicines and Healthcare ...
Results from the phase 3 ICONIC-LEAD study presented at this year’s American Academy of Dermatology (AAD) annual meeting ...
Medscape is proud to highlight Michelle A. Worst, PharmD, BCOP, MBA, CHCP, Senior Director and Team Lead of Clinical Strategy ...
Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been approved by the European Commission ...
Organon has shared positive results from a long-term extension (LTE) study of its Vtama (tapinarof) cream, 1% in atopic ...